Healio (9/4, Herpen) reports a study found that “lumateperone as adjunctive therapy led to greater symptom improvement for those with major depressive disorder and a history of inadequate therapeutic response to prior medication compared with placebo.” Study participants “included 485 individuals aged 18 to 65 years who previously were prescribed one or two ADTs during a current depressive episode with no resolution,” plus high scores on MADRS, CGI-S, and QIDS-SR-16. The researchers “found that treatment with lumateperone plus ADT led to greater mean improvement in total scores by day 43 compared with placebo in all three metrics.” They “additionally reported that lumateperone plus ADT was generally well-tolerated, with treatment-emergent adverse events occurring in 46.5% of the placebo plus ADT group and in 58.1% of the lumateperone plus ADT group.” The study was published in the Journal of Clinical Psychiatry. (SOURCE: APA Headlines)